CELLforCURE by SEQENS is an EMA-authorized CDMO specializing in the advancement of cell and gene therapies from development through to commercialization. Acquired by SEQENS in December 2023, the Les Ulis, France–based facility encompasses 2,200 square meters of GMP production space, featuring six modular and flexible manufacturing lines. With over a decade of experience, CELLforCURE offers comprehensive services, including process and analytical development, technology transfer, quality control, GMP manufacturing, and product release — all within a fully integrated, one-stop-shop facility — to support clients from early-stage development to commercial production.